The monoamine oxidase inhibitory activity of essential oils obtained from Eryngium species and their chemical composition.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 9812552 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-5116 (Electronic) Linking ISSN: 13880209 NLM ISO Abbreviation: Pharm Biol Subsets: MEDLINE
    • Publication Information:
      Publication: [London] : Taylor & Francis
      Original Publication: Lisse, the Netherlands : Swets & Zeitlinger, c1998-
    • Subject Terms:
      Eryngium/*chemistry ; Mitochondria/*enzymology ; Monoamine Oxidase/*metabolism ; Monoamine Oxidase Inhibitors/*pharmacology ; Oils, Volatile/*pharmacology ; Plant Oils/*pharmacology; Dose-Response Relationship, Drug ; Gas Chromatography-Mass Spectrometry ; Humans ; In Vitro Techniques ; Monoamine Oxidase Inhibitors/isolation & purification ; Oils, Volatile/isolation & purification ; Plant Oils/isolation & purification
    • Abstract:
      Context: Monoamine oxidase (MAO) inhibitors are used in the treatment of depression, anxiety disorders, and the symptomatic treatment of Parkinson's disease. Eryngium, the most representative of the Apiaceae family, is well known for the presence of essential oils (EOs), which have already demonstrated MAO inhibitory potential.
      Objective: The objective of this study is to evaluate the MAO inhibitory capacity of the EOs obtained from Eryngium floribundum Cham. & Schlecht. (EF), E. eriophorum Cham. & Schlecht. (EE), E. nudicaule Lam. (EN), E. horridum Malme (EH), and E. pandanifolium Cham. & Schlecht. (EP).
      Materials and Methods: EOs were obtained from fresh whole plants by hydrodistillation (3 h). Chemical analyses were performed by GC/MS using apolar and polar columns, with oven temperature from 60 to 300 °C at 3 °C/min. The MAO-A and -B activities were evaluated in vitro by an end-point method using kynuramine as the substrate and mitochondrial suspension or human recombinant enzymes as the enzymatic source. DMSO 2%, clorgyline 10(-7) M, and pargyline 10(-6) M were used as controls.
      Results and Discussion: EFEO, EEEO, ENEO, EHEO, and EPEO GC/MS analysis showed (E)-caryophyllene (4.9-10.8%), germacrene D (0.6-35.1%), bicyclogermacrene (10.4-17.2), spathulenol (0.4-36.0%), and globulol (1.4-18.6%) as main constituents. None of the EOs inhibited MAO-A activity (4 and 40 μg/mL). However, EHEO inhibited MAO-B activity with an IC50 value of 5.65 μg/mL (1-200 μg/mL). Pentadecane (10 μM), its major constituent (53.5%), did not display significant MAO-B inhibition.
      Conclusion: The study demonstrates the promising application of Eryngium species as a source of potential central nervous system bioactive secondary metabolites, specially related to neurodegenerative disorders.
    • References:
      J Ethnopharmacol. 2007 Sep 25;113(3):363-81. (PMID: 17720341)
      BMC Neurol. 2011 Sep 22;11:112. (PMID: 21939547)
      Mol Phylogenet Evol. 2008 Mar;46(3):1129-50. (PMID: 18178486)
      J Ethnopharmacol. 2006 Aug 11;107(1):32-7. (PMID: 16529889)
      J Pharm Biomed Anal. 2011 Feb 20;54(3):619-22. (PMID: 21036502)
      Biochim Biophys Acta. 1980 Apr 24;597(3):445-63. (PMID: 6892885)
      Molecules. 2011 Aug 19;16(8):7115-24. (PMID: 25134776)
      FEBS Lett. 2004 Apr 30;564(3):225-8. (PMID: 15111100)
      Bioorg Med Chem. 2005 Nov 15;13(22):6212-7. (PMID: 16054369)
      J Pharm Biomed Anal. 1993 Jul;11(7):563-8. (PMID: 8399530)
      J Enzyme Inhib Med Chem. 2013 Jun;28(3):611-8. (PMID: 22424181)
      Methods Biochem Anal. 2005;46:1-265. (PMID: 16350889)
      J Chromatogr A. 2005 May 13;1074(1-2):235-9. (PMID: 15941061)
      J Chromatogr A. 2005 Nov 11;1094(1-2):179-82. (PMID: 16202420)
      Bioorg Med Chem. 2005 Aug 1;13(15):4777-88. (PMID: 15936201)
      Biochim Biophys Acta. 1988 Mar 22;939(1):64-78. (PMID: 3349082)
      Nat Rev Neurosci. 2006 Apr;7(4):295-309. (PMID: 16552415)
      Int Rev Neurobiol. 2011;100:169-90. (PMID: 21971008)
      Phytomedicine. 2001 Sep;8(5):401-9. (PMID: 11695885)
      J Chromatogr A. 2007 Dec 21;1175(2):289-93. (PMID: 18022631)
      Br J Pharmacol. 2006 Jan;147 Suppl 1:S287-96. (PMID: 16402116)
      J Ethnopharmacol. 2010 Feb 3;127(2):319-24. (PMID: 19913082)
      Mini Rev Med Chem. 2012 Sep 1;12(10):907-19. (PMID: 22420569)
    • Contributed Indexing:
      Keywords: Neurodegeneration; Parkinson's disease; pentadecane
    • Accession Number:
      0 (Monoamine Oxidase Inhibitors)
      0 (Oils, Volatile)
      0 (Plant Oils)
      EC 1.4.3.4 (Monoamine Oxidase)
    • Publication Date:
      Date Created: 20160127 Date Completed: 20170106 Latest Revision: 20240530
    • Publication Date:
      20240530
    • Accession Number:
      PMC11132605
    • Accession Number:
      10.3109/13880209.2015.1102949
    • Accession Number:
      26810928